<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2015122721890N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-01-25</date_registration>
      <primary_sponsor>Vice Chancellor for Research, Isfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of the laser photocoagulation method in treatment of diabetic macular edema</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema in the years of 2015-2016 at the Isfahan Feiz hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/19037</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>diabetic macular edema.</hc_freetext>
      <i_freetext>Intervention 1: After getting informed consent we will be studied 68 eyes that randomly will divide in two groups.&#13;
First group will be get subthreshold diode micropulse laser photocoagulation (Quantel-medical Co, USA) as described below: adjustable power that begins of 1000 millivolt with duration time of 300 microseconds, 15 % of duty cycle and 75 to 125 microns spot size. All areas of thickened and edematous retina will be treated with distance of 100 microns of the FAZ in this method. Intervention 2: Conventional laser photocoagulation (Quantel-medical Co, USA) will be performed via dilated pupil in eyes of second group as described below: adjustable power with 50 to 100 microns spot size, 0.1 second duration time. Focal laser will be applied in distance of 500 to 3000 microns of the foveal avascular zone (FAZ) and also on microvascular lesions of the exudative ring, also grid laser will be applied on thickened retinal areas in 500 microns distance of the FAZ and 500 microns distance of temporal ridge of optic disc.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Majid Bagheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Feiz Eye Center hospital, Modaress Street, Ghods Square, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 3445 2033</telephone>
        <email>bagheri.majid0612@gmail.com</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Farhad Fazel</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Feiz Eye Center Hospital, Ghods Square, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 3445 2033</telephone>
        <email>fazel@med.mui.ac.ir</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: at least best corrected vision 20/200 or 1.00 LogMAR; the best corrected vision less than 20/25 or 0.10 LogMAR; diabetic macular edema with at least central macular thickness of 300 microns&#13;
Exclusion criteria: monocular patients; diabetic macular edema with central macular thickness more than 450 microns; pregnant patients; uncontrolled diabetes mellitus defined with fasting blood glucose (FBS) more than 300 mg/dl and or Hb A1c˃10 mg/dl; uncontrolled hypertension defined with systolic blood pressure SBP more than 160 mmHg and or diastolic blood pressure (DBP) more than 110 mmHg; any history of intra orbital surgery except uncomplicated cataract surgery with phacoemulsification method; any history of previously intra ocular injection; any history of previously conventional laser photocoagulation of retina or subthreshold diode micropulse laser; previously history of glaucoma or ocular hypertension; macular diseases like vitreo macular traction(VMT), Epi retinal Membrane (ERM), Age related macular degeneration (AMD), proliferative diabetic retinopathy (PDR); extensive non capillary perfusion in fundus angiography of macula; pregnancy during the study; any visible scar in ophthalmic examination or fundus angiography during the study in group that treated with subthreshold diode micropulse laser; not follow up of patients; no acceptance to perform study.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H36.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetic retinopathy (E10-E14 with common fourth character .3+)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>After getting informed consent we will be studied 68 eyes that randomly will divide in two groups.&#13;
First group will be get subthreshold diode micropulse laser photocoagulation (Quantel-medical Co, USA) as described below: adjustable power that begins of 1000 millivolt with duration time of 300 microseconds, 15 % of duty cycle and 75 to 125 microns spot size. All areas of thickened and edematous retina will be treated with distance of 100 microns of the FAZ in this method.</i_keyword>
      <i_keyword>Conventional laser photocoagulation (Quantel-medical Co, USA) will be performed via dilated pupil in eyes of second group as described below: adjustable power with 50 to 100 microns spot size, 0.1 second duration time. Focal laser will be applied in distance of 500 to 3000 microns of the foveal avascular zone (FAZ) and also on microvascular lesions of the exudative ring, also grid laser will be applied on thickened retinal areas in 500 microns distance of the FAZ and 500 microns distance of temporal ridge of optic disc.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Best corrected visual acuity. Timepoint: 0, ,2, 4 Months. Method of measurement: With Snellen chart and then converted to LogMAR.</prim_outcome>
      <prim_outcome>The mean of central macular thickness. Timepoint: 0, ,2, 4 Months. Method of measurement: With optical coherence tomography (OCT) imaging technique (Microns).</prim_outcome>
      <prim_outcome>The mean of central macular volume. Timepoint: 0, ,2, 4 Months. Method of measurement: With optical coherence tomography (OCT) imaging technique (Microns).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Complications of the conventional laser photocoagulation. Timepoint: 2, 4 Months. Method of measurement: Fundus examination and fluorescein angiography.</sec_outcome>
      <sec_outcome>Complications of the subthreshold diode micropulse laser. Timepoint: 2, 4 Months. Method of measurement: Fundus examination and fluorescein angiography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research, Isfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-11-11</approval_date>
        <contact_name>Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, Hezar Jarib Street Isfahan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
